GBT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (5 Oct 2022 @ 04:00):

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD)...

Stats
今日成交量	3.28M
平均成交量	0
市值	0.00
EPS	$0 ( 2022-11-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.08
ATR14	$0.890 (1.30%)

Insider Trading

Date	Person	Action	Amount	type
2022-10-05	Perry Mark L	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Patrick Deval L	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Morrison Scott W	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Thompson Alexis A.	Sell	3 600	Restricted Stock Units
2022-10-05	Yarno Wendy L	Sell	30 000	Stock Option (Right to Buy)

INSIDER POWER
-60.35
Last 100 transactions
Buy: 278 284 \| Sell: 1 075 911

音量相关性

長: 0.35 (neutral)

短: 0.93 (very strong)

Signal:(77.112) Expect same movement, but be aware

Global Blood 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Global Blood 相关性 - 货币/商品

0.94
( very strong )

0.92
( very strong )

-0.79
( moderate negative )

0.83
( strong )

0.23
( neutral )

-0.61
( weak negative )

Global Blood 财务报表

Annual	2021
营收:	$194.75M
毛利润:	$191.43M (98.30 %)
EPS:	$-4.82

FY	2021
营收:	$194.75M
毛利润:	$191.43M (98.30 %)
EPS:	$-4.82

FY	2020
营收:	$123.80M
毛利润:	$121.82M (98.40 %)
EPS:	$-4.04

FY	2019
营收:	$2.11M
毛利润:	$2.06M (97.72 %)
EPS:	$-4.57

Financial Reports:

No articles found.

Global Blood

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.